The KATHERINE trial included 1,486 patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer who had residual invasive disease in the breast or axillary lymph node ...

The KATHERINE trial included 1,486 patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer who had residual invasive disease in the breast or axillary lymph node ...

Launched in 2012, the multinational KATHERINE trial involved almost 1,500 women with HER2-positive breast cancer and residual disease in the breast or axillary lymph nodes after neoadjuvant ...

A 41-year-old man was evaluated for swelling in the ankles and syncope. CT of the chest showed bilateral mediastinal and ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

However, lymph node swelling, a known side effect of the ... Despite normal hormone levels in her blood tests, prescribed steroids and antibiotics failed to halt the growth. Her condition ...

Axillary lymph node metastasis from ovarian cancer is extremely rare and ... The patient’s treatment response, tracked through tumor marker levels, is shown in Figure 3G. Following treatment with ...

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

Our editors also may be in touch with follow-up questions. Of the many health metrics to monitor, blood sugar levels are of great significance, as they can serve as an indicator of overall health.